Migraine - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Migraine - Pipeline Review, H1 2016', provides an overview of the Migraine pipeline landscape. The report provides comprehensive information on the therapeutics under development for Migraine, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews pipeline therapeutics for Migraine by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Migraine therapeutics and enlists all their major and minor projects - The report assesses Migraine therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Migraine Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Migraine - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Migraine Overview 7 Therapeutics Development 8 Migraine - Therapeutics under Development by Companies 10 Migraine - Therapeutics under Investigation by Universities/Institutes 14 Migraine - Pipeline Products Glance 15 Migraine - Products under Development by Companies 19 Migraine - Products under Investigation by Universities/Institutes 23 Migraine - Companies Involved in Therapeutics Development 24 Migraine - Therapeutics Assessment 63 Drug Profiles 78 Migraine - Recent Pipeline Updates 164 Migraine - Dormant Projects 194 Migraine - Discontinued Products 200 Migraine - Product Development Milestones 201 Appendix 210
List of Tables
Number of Products under Development for Migraine, H1 2016 16 Number of Products under Development for Migraine - Comparative Analysis, H1 2016 17 Number of Products under Development by Companies, H1 2016 19 Number of Products under Development by Companies, H1 2016 (Contd..1) 20 Number of Products under Development by Companies, H1 2016 (Contd..2) 21 Number of Products under Investigation by Universities/Institutes, H1 2016 22 Comparative Analysis by Late Stage Development, H1 2016 23 Comparative Analysis by Clinical Stage Development, H1 2016 24 Comparative Analysis by Early Stage Development, H1 2016 25 Comparative Analysis by Unknown Stage Development, H1 2016 26 Products under Development by Companies, H1 2016 27 Products under Development by Companies, H1 2016 (Contd..1) 28 Products under Development by Companies, H1 2016 (Contd..2) 29 Products under Development by Companies, H1 2016 (Contd..3) 30 Products under Investigation by Universities/Institutes, H1 2016 31 Migraine - Pipeline by Achelios Therapeutics, Inc., H1 2016 32 Migraine - Pipeline by Acorda Therapeutics, Inc., H1 2016 33 Migraine - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016 34 Migraine - Pipeline by Alder Biopharmaceuticals Inc., H1 2016 35 Migraine - Pipeline by Allergan Plc, H1 2016 36 Migraine - Pipeline by Amgen Inc., H1 2016 37 Migraine - Pipeline by Aralez Pharmaceuticals Inc., H1 2016 38 Migraine - Pipeline by Astellas Pharma Inc., H1 2016 39 Migraine - Pipeline by Biofrontera AG, H1 2016 40 Migraine - Pipeline by Bristol-Myers Squibb Company, H1 2016 41 Migraine - Pipeline by Charleston Laboratories, Inc., H1 2016 42 Migraine - Pipeline by CoLucid Pharmaceuticals, Inc., H1 2016 43 Migraine - Pipeline by Corium International, Inc., H1 2016 44 Migraine - Pipeline by D-Pharm Ltd., H1 2016 45 Migraine - Pipeline by Eli Lilly and Company, H1 2016 46 Migraine - Pipeline by iCeutica, Inc., H1 2016 47 Migraine - Pipeline by Impel NeuroPharma, Inc., H1 2016 48 Migraine - Pipeline by Klaria Pharma Holding AB, H1 2016 49 Migraine - Pipeline by Mallinckrodt Plc, H1 2016 50 Migraine - Pipeline by Medestea Research & Production S.p.A., H1 2016 51 Migraine - Pipeline by Merck & Co., Inc., H1 2016 52 Migraine - Pipeline by Mithra Pharmaceuticals S.A., H1 2016 53 Migraine - Pipeline by Monosol Rx, LLC, H1 2016 54 Migraine - Pipeline by NAL Pharmaceuticals Ltd., H1 2016 55 Migraine - Pipeline by Noxxon Pharma AG, H1 2016 56 Migraine - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 57 Migraine - Pipeline by Pivot Pharmaceuticals Inc, H1 2016 58 Migraine - Pipeline by Promius Pharma, LLC, H1 2016 59 Migraine - Pipeline by RedHill Biopharma Ltd., H1 2016 60 Migraine - Pipeline by Revance Therapeutics, Inc., H1 2016 61 Migraine - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H1 2016 62 Migraine - Pipeline by Suda Ltd, H1 2016 63 Migraine - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 64 Migraine - Pipeline by TheraJect, Inc., H1 2016 65 Migraine - Pipeline by Tonix Pharmaceuticals Holding Corp., H1 2016 66 Migraine - Pipeline by Trevena, Inc., H1 2016 67 Migraine - Pipeline by Trigemina, Inc., H1 2016 68 Migraine - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 69 Migraine - Pipeline by Zosano Pharma Corporation, H1 2016 70 Assessment by Monotherapy Products, H1 2016 71 Assessment by Combination Products, H1 2016 72 Number of Products by Stage and Target, H1 2016 74 Number of Products by Stage and Mechanism of Action, H1 2016 79 Number of Products by Stage and Route of Administration, H1 2016 83 Number of Products by Stage and Molecule Type, H1 2016 85 Migraine Therapeutics - Recent Pipeline Updates, H1 2016 172 Migraine - Dormant Projects, H1 2016 202 Migraine - Dormant Projects (Contd..1), H1 2016 203 Migraine - Dormant Projects (Contd..2), H1 2016 204 Migraine - Dormant Projects (Contd..3), H1 2016 205 Migraine - Dormant Projects (Contd..4), H1 2016 206 Migraine - Dormant Projects (Contd..5), H1 2016 207 Migraine - Discontinued Products, H1 2016 208
Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from mainRead More...
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likelyRead More...
Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmaceRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.